ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Start your engineering — CARs take to the TRAC – Nature.com

Continue reading

2017-03-20 Michael Zand NEWS

Immunotherapy: a new treatment paradigm in bladder cancer. – UroToday

Immunotherapy: a new treatment paradigm in bladder cancer.UroTodayT-cell checkpoint blockade has become a dynamic immunotherapy for bladder cancer. In 2016, atezolizumab, an immune checkpoint inhibitor, became the first new drug approved in metastatic … Continue reading

2017-03-20 Michael Zand NEWS

Immunotherapy: a new treatment paradigm in bladder cancer. – UroToday

Immunotherapy: a new treatment paradigm in bladder cancer.UroTodayT-cell checkpoint blockade has become a dynamic immunotherapy for bladder cancer. In 2016, atezolizumab, an immune checkpoint inhibitor, became the first new drug approved in metastatic … Continue reading

2017-03-20 Michael Zand NEWS

Orbis Research Adds a New Report Global T-Cell Immunotherapy Market 2017 Forecast – Medgadget (blog)

Start your engineering — CARs take to the TRAC
Nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) that recognize tumour-associated antigens are promising anticancer agents. In particular, anti-CD19 CAR T cells can induce complete remission in patients with B-cell malignancies.

Continue reading

2017-03-20 Michael Zand NEWS

Gene therapy hope for blindness – NEWS.com.au

Orbis Research Adds a New Report Global T-Cell Immunotherapy Market 2017 Forecast
Medgadget (blog)
The Global T-Cell Immunotherapy market report offers a comprehensive evaluation of the Global T-Cell Immunotherapy industry. This report evaluates the Global market for “Global T-Cell Immunotherapy “. The Global T-Cell Immunotherapy market report …

and more »

Continue reading

2017-03-20 Michael Zand NEWS

Gene therapy hope for blindness – The Australian – The Australian


The Sun

Gene therapy hope for blindness
NEWS.com.au
On March 16, a 29-year-old man became the first patient to undergo the gene therapy procedure at Oxford Eye Hospital. The trial team hopes to recruit up to 30 patients for the study, which is designed to assess safety and tolerability rather than …
NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial …Yahoo Finance
Brit scientists testing ‘groundbreaking’ therapy that could cure common cause of blindnessThe Sun
New trial for blindness rewrites the genetic codeMedical Xpress
Telegraph.co.uk –The Express Tribune –BBC News
all 6 news articles »
Continue reading

2017-03-20 Michael Zand NEWS

Gene therapy hope for blindness | SBS News – SBS


The Sun

Gene therapy hope for blindness – The Australian
The Australian
A gene therapy treatment for the most common cause of blindness in young people is being tested in a group of British trial patients.
Brit scientists testing ‘groundbreaking’ therapy that could cure …The Sun
BBC World Service – Newsday, Hereditary blindness cure testedBBC News

all 3 news articles »

Continue reading

2017-03-20 Michael Zand NEWS

NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa – Yahoo Finance


The Sun

Gene therapy hope for blindness | SBS News
SBS
Researchers aim to use a virus to carry corrective DNA into cells at the back of the eye as a therapy for the most common cause of blindness in young people.
Brit scientists testing ‘groundbreaking’ therapy that could cure …The Sun
BBC World Service – Newsday, Hereditary blindness cure testedBBC News

all 3 news articles »

Continue reading

2017-03-20 Michael Zand NEWS
  • 1
  • …
  • 1,957
  • 1,958
  • 1,959
  • 1,960
  • 1,961
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Telegraph.co.uk

NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa
Yahoo Finance
NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announces that the Company has commenced enrolling and dosing subjects in a Phase I/II clinical trial to treat …
Blind British man in world’s first operation to deliver modified DNA to his eyesTelegraph.co.uk

all 2 news articles »